Next Generation Cancer Diagnostics Market Report 2026

The next generation cancer diagnostics market size has grown rapidly in recent years. It will grow from $14.4 billion in 2025 to $16.29 billion in 2026 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increasing cancer incidence rates, advancements in genomic sequencing technologies, growing clinical adoption of biomarker-based diagnostics, expansion of oncology research funding, rising demand for precision diagnostics.

The next generation cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $26.44 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine approaches, rising investments in advanced cancer screening programs, growing use of minimally invasive diagnostic methods, expansion of companion diagnostics development, increasing integration of ai-driven clinical decision support. Major trends in the forecast period include increasing adoption of liquid biopsy technologies, rising use of multi-omics diagnostic platforms, growing integration of AI-based cancer analytics, expansion of personalized oncology diagnostics, enhanced focus on early-stage cancer detection.

The increasing demand for personalized medicines is expected to drive the growth of the next generation cancer diagnostics market in the coming years. Personalized medicines are treatments tailored to an individual’s genetic profile, lifestyle, and environment to deliver the most effective therapy for that patient. This growing demand is fueled by the rising prevalence of chronic and rare diseases, which require targeted, patient-specific therapies for improved treatment outcomes. Next generation cancer diagnostics support personalized medicine by offering precise molecular insights that guide tailored treatment strategies based on a patient’s unique genetic and tumor characteristics. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for rare disease patients in 2023, a significant increase from six approvals in 2022. Consequently, the rising demand for personalized medicines is propelling the next generation cancer diagnostics market.

Major players in the next generation cancer diagnostics market are focusing on developing innovative solutions, such as artificial intelligence-powered multi-modal diagnostic platforms, to improve early detection, personalized treatment, and clinical decision-making. These platforms integrate and analyze multiple types of biological data, including genomic, proteomic, imaging, and clinical information, to deliver more accurate and personalized cancer detection and diagnosis. For instance, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, launched OncoIncytes, a multi-modal cancer diagnostic platform for precision oncology. The platform combines circulating tumor DNA, single-cell circulating tumor cells, RNA data, and detailed protein profiles of 150 proteins at the single-cell level. Using a 1080-gene panel powered by AI and machine learning, OncoIncytes provides highly sensitive and specific insights to improve clinical trial outcomes, especially in early-stage research and antibody-drug conjugate development. The platform allows personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, accessible via OneCell’s proprietary iDiscover application from a CLIA-certified laboratory.

In June 2023, Quest Diagnostics Inc., a US-based healthcare diagnostics company, acquired Haystack Oncology for an undisclosed sum. This acquisition aimed to strengthen Quest Diagnostics’ capabilities in the rapidly growing minimal residual disease (MRD) liquid biopsy market. Haystack Oncology Inc., also US-based, provides next-generation cancer diagnostics through its tumor-informed MRD test, Haystack MRD.

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.

North America was the largest region in the next generation cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next generation cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the next generation cancer diagnostics market by increasing costs of imported sequencing instruments, reagents, microfluidic chips, imaging components, and advanced laboratory equipment used across genomic and proteomic platforms. Diagnostic laboratories and research institutions in North America and Europe are most affected due to reliance on imported high-precision instruments, while Asia-Pacific faces cost pressure on reagent and consumable supplies. These tariffs are elevating testing costs and slowing technology upgrades. However, they are also encouraging local manufacturing of diagnostic kits, regional reagent production, and domestic innovation in cost-efficient cancer diagnostic technologies.

The next generation cancer diagnostics market research report is one of a series of new reports that provides next generation cancer diagnostics market statistics, including next generation cancer diagnostics industry global market size, regional shares, competitors with a next generation cancer diagnostics market share, detailed next generation cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the next generation cancer diagnostics industry. This next generation cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Next-generation cancer diagnostics involve advanced technologies that allow for accurate detection, characterization, and monitoring of cancer at the molecular and genetic levels. These diagnostics employ state-of-the-art tools such as genomics, proteomics, and liquid biopsy to enable early detection, personalized treatment planning, and enhanced patient outcomes.

The primary technologies in next-generation cancer diagnostics include next-generation sequencing (NGS), q-polymerase chain reaction and multiplexing, lab-on-a-chip (LOAC) and reverse transcriptase-polymerase chain reaction (RT-PCR), circulating tumor DNA (ctDNA) assays, protein microarrays, DNA microarrays, and others. Next-generation sequencing (NGS) is a high-throughput DNA sequencing method that allows rapid and simultaneous sequencing of millions of DNA fragments, facilitating comprehensive analysis of genomes, transcriptomes, and genetic variations. These technologies address various cancer types, including lung, breast, colorectal, and cervical cancers. Their applications include therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk assessment. They are used for biomarker development, circulating tumor cell (CTC) analysis, proteomic studies, epigenetic research, and genetic analysis, serving end users such as hospitals and clinics, diagnostic laboratories, research and academic institutions, pharmaceutical and biotechnology companies, and home care environments.

The next generation cancer diagnostics market consists of revenues earned by entities by providing services such as genomic and molecular profiling, liquid biopsy testing, next-generation sequencing (NGS) services, companion diagnostics development, and bioinformatics and data interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The next generation cancer diagnostics market also includes sales of gene panels, single-cell analysis systems, nanotechnology-based biosensors, molecular imaging agents, and exosome isolation kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.